MA31821B1 - Anticorps anti-cxcr5 humanises, leurs derives et leurs utilisations - Google Patents

Anticorps anti-cxcr5 humanises, leurs derives et leurs utilisations

Info

Publication number
MA31821B1
MA31821B1 MA32673A MA32673A MA31821B1 MA 31821 B1 MA31821 B1 MA 31821B1 MA 32673 A MA32673 A MA 32673A MA 32673 A MA32673 A MA 32673A MA 31821 B1 MA31821 B1 MA 31821B1
Authority
MA
Morocco
Prior art keywords
derivatives
cxcr5
humanized anti
cxcr5 antibodies
antibodies
Prior art date
Application number
MA32673A
Other languages
Arabic (ar)
English (en)
Inventor
Renata Lee
Vincent Mikol
Elizabeth Allen
Norman Ruetsch
Beatrice Cameron
Thomas Oligino
Nicolas Baurin
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40429297&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31821(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA31821B1 publication Critical patent/MA31821B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Evolutionary Biology (AREA)
  • Physiology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)

Abstract

La présente invention porte sur des anticorps humanisés qui se lient spécifiquement à CXCR5 et qui peuvent, par exemple, inhiber la fonction CXCR5. L'invention inclut également des utilisations des anticorps pour traiter ou prévenir des maladies ou des troubles liés à CXCR5.
MA32673A 2007-08-29 2010-03-08 Anticorps anti-cxcr5 humanises, leurs derives et leurs utilisations MA31821B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96879207P 2007-08-29 2007-08-29
PCT/US2008/074381 WO2009032661A1 (fr) 2007-08-29 2008-08-27 Anticorps anti-cxcr5 humanisés, leurs dérivés et leurs utilisations

Publications (1)

Publication Number Publication Date
MA31821B1 true MA31821B1 (fr) 2010-11-01

Family

ID=40429297

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32673A MA31821B1 (fr) 2007-08-29 2010-03-08 Anticorps anti-cxcr5 humanises, leurs derives et leurs utilisations

Country Status (44)

Country Link
US (9) US8647622B2 (fr)
EP (3) EP3792284A1 (fr)
JP (3) JP5743543B2 (fr)
KR (4) KR101701140B1 (fr)
CN (4) CN104017078B (fr)
AR (2) AR068354A1 (fr)
AU (1) AU2008296538B2 (fr)
BR (1) BRPI0815983A2 (fr)
CA (1) CA2698203C (fr)
CL (1) CL2008002565A1 (fr)
CO (1) CO6270238A2 (fr)
CR (2) CR11293A (fr)
CY (1) CY1120665T1 (fr)
DK (1) DK2195023T3 (fr)
DO (1) DOP2010000069A (fr)
EC (1) ECSP109985A (fr)
ES (1) ES2672769T3 (fr)
HR (1) HRP20180873T1 (fr)
HU (1) HUE037489T2 (fr)
IL (2) IL204173A (fr)
LT (1) LT2195023T (fr)
MA (1) MA31821B1 (fr)
MX (5) MX346172B (fr)
MY (1) MY159201A (fr)
NI (2) NI201000281A (fr)
NO (1) NO2195023T3 (fr)
NZ (1) NZ583605A (fr)
PA (1) PA8794201A1 (fr)
PE (1) PE20090993A1 (fr)
PH (1) PH12015500248A1 (fr)
PL (1) PL2195023T3 (fr)
PT (1) PT2195023T (fr)
RS (1) RS57273B1 (fr)
RU (2) RU2015147300A (fr)
SG (1) SG10201407388XA (fr)
SI (1) SI2195023T1 (fr)
SV (1) SV2010003494A (fr)
TN (1) TN2010000092A1 (fr)
TR (1) TR201807983T4 (fr)
TW (4) TWI608017B (fr)
UA (2) UA104715C2 (fr)
UY (1) UY31309A1 (fr)
WO (1) WO2009032661A1 (fr)
ZA (1) ZA201001514B (fr)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120263733A1 (en) * 2002-11-15 2012-10-18 Morehouse School Of Medicine Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation
MY157757A (en) 2006-07-18 2016-07-15 Sanofi Aventis Antagonist antibody against epha2 for the treatment of cancer
NO2195023T3 (fr) 2007-08-29 2018-08-04
US20110144311A1 (en) * 2008-08-14 2011-06-16 Rebecca Chmielowski Methods for purifying antibodies using protein a affinity chromatography
FR2945538B1 (fr) 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
TW201116297A (en) 2009-10-02 2011-05-16 Sanofi Aventis Antibodies that specifically bind to the EphA2 receptor
MX343228B (es) * 2009-11-30 2016-10-26 Biotest Ag Anticuerpos anti-il-10humanizados para el tratamiento de lupus sistémico eritematoso.
EP2336188A1 (fr) 2009-12-18 2011-06-22 Sanofi-Aventis Nouveaux anticorps antagonistes et leurs fragments Fab contre le GPVI et leurs utilisations
EP2397495A1 (fr) 2010-06-21 2011-12-21 Sanofi Nouveaux anticorps antagonistes et leurs fragments Fab contre le GPVI et leurs utilisations
DK2513147T3 (en) 2009-12-18 2016-10-24 Sanofi Sa Hitherto UNKNOWN ANTAGONIST ANTIBODIES AND THEIR FAB FRAGMENTS AGAINST GPVI AND USES THEREOF
EP2402371A1 (fr) 2010-07-01 2012-01-04 Sanofi Nouveaux anticorps antagonistes et leurs fragments Fab contre le GPVI et leurs utilisations
FR2958936A1 (fr) 2010-04-14 2011-10-21 Sanofi Aventis Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs
WO2012010582A1 (fr) 2010-07-21 2012-01-26 Roche Glycart Ag Anticorps anti-cxcr5 et leurs méthodes d'utilisation
TWI560199B (en) 2010-08-31 2016-12-01 Sanofi Sa Peptide or peptide complex binding to α2 integrin and methods and uses involving the same
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
CN106177930A (zh) * 2010-12-14 2016-12-07 吉安特科技股份有限公司 抗cxcl13抗体和抗cxcr5抗体在恶性肿瘤的治疗或检测中的用途
AR085302A1 (es) 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
ES2698606T3 (es) 2012-01-20 2019-02-05 Genzyme Corp Anticuerpos anti-CXCR3
ES2702246T3 (es) * 2012-03-26 2019-02-28 Sanofi Sa Formulaciones de agente de unión IgG4 estables
EP3431104A1 (fr) 2012-03-26 2019-01-23 Sanofi Formulations d'agents de liaison igg4 stables
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
MY184037A (en) 2012-03-28 2021-03-17 Sanofi Sa Antibodies to bradykinin b1 receptor ligands
CN107478843A (zh) * 2012-06-27 2017-12-15 吉安特科技公司 用于炎性疾病的抗‑cxcl9、抗‑cxcl10、抗‑cxcl11、抗‑cxcl13、抗‑cxcr3和抗‑cxcr5试剂
CN104870013A (zh) * 2012-06-27 2015-08-26 吉安特科技公司 用于抑制炎症的抗-cxcl9、抗-cxcl10、抗-cxcl11、抗-cxcl13、抗-cxcr3和抗-cxcr5试剂
CA2889962C (fr) 2012-11-20 2023-10-24 Sanofi Anticorps anti-ceacam5 et leurs utilisations
EP2925779A1 (fr) 2012-11-30 2015-10-07 Institut Pasteur Utilisation d'anticorps anti-fcyri et/ou anti-fcyriia pour traiter une arthrite, une inflammation, une thrombopénie et un choc anaphylactique
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
EA201690004A1 (ru) 2012-12-27 2016-07-29 Санофи Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение
TWI612059B (zh) * 2013-03-15 2018-01-21 美國禮來大藥廠 泛－ＥＬＲ<sup>＋</sup>ＣＸＣ趨化因子抗體
JP6522585B2 (ja) * 2013-05-02 2019-05-29 アレス トレーディング ソシエテ アノニム Ｃｘｃｒ５に対するモノクローナル抗体
BR112015032277B1 (pt) * 2013-06-24 2020-12-01 Neximmune complexo de apresentação de antígeno, seu uso, e composição
CN112142845A (zh) 2013-08-13 2020-12-29 赛诺菲 纤溶酶原激活剂抑制剂-1(pai-1)的抗体及其用途
TW201722994A (zh) 2013-08-13 2017-07-01 賽諾菲公司 胞漿素原活化素抑制劑-１（ｐａｉ-１）之抗體及其用途
US10881085B2 (en) * 2014-03-21 2021-01-05 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
US9765146B2 (en) * 2014-08-22 2017-09-19 Sorrento Therapeutics, Inc. Fully human anti-CXC chemokine receptor 5 (CXCR5) antibodies
CN116869964A (zh) * 2014-12-24 2023-10-13 耐克西缪恩有限公司 用于免疫疗法的纳米颗粒组合物和方法
UA126269C2 (uk) 2015-01-23 2022-09-14 Санофі АНТИТІЛОПОДІБНИЙ ЗВ’ЯЗУВАЛЬНИЙ БІЛОК, ЯКИЙ СПЕЦИФІЧНО ЗВ’ЯЗУЄТЬСЯ З ПОЗАКЛІТИННИМ ДОМЕНОМ CD3<font face="Symbol">e</font> ЛЮДИНИ І З CD123<font face="Symbol">e</font>
EP3313523A2 (fr) 2015-06-23 2018-05-02 Bayer Pharma Aktiengesellschaft Conjugués ciblés d'inhibiteurs de ksp
AU2016349152A1 (en) 2015-11-03 2018-06-14 Merck Patent Gmbh Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof
CN110452295B (zh) * 2015-11-10 2022-10-11 孙嘉琳 抗肿瘤蛋白内皮抑素的衍生物
JP7251981B2 (ja) 2016-03-24 2023-04-04 バイエル ファーマ アクチエンゲゼルシャフト 酵素開裂基を有する細胞毒性活性剤のプロドラッグ
EP3919518A1 (fr) 2016-06-15 2021-12-08 Bayer Pharma Aktiengesellschaft Conjugués anticorps-médicament spécifiques (adc) avec inhibiteurs de ksp et des anticorps anti-cd123
CA3029642A1 (fr) * 2016-07-05 2018-01-11 Sanofi Formule d'anticorps.
TWI760345B (zh) 2016-07-05 2022-04-11 法商賽諾菲公司 抗體調配物
TWI790206B (zh) 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
US11787855B2 (en) 2016-09-26 2023-10-17 Mpo, Inc. Egg, fertilized egg, or embryo quality improving agent
EP3558388A1 (fr) 2016-12-21 2019-10-30 Bayer Pharma Aktiengesellschaft Conjugués liant-principe actif (adc) ayant des groupes enzymatiquement clivables
WO2018114798A1 (fr) 2016-12-21 2018-06-28 Bayer Aktiengesellschaft Promédicaments de principes actifs cytotoxiques contenant des groupes divisibles par voie enzymatique
JP7030811B2 (ja) 2016-12-21 2022-03-07 バイエル・ファルマ・アクティエンゲゼルシャフト Ｋｓｐ阻害剤を有する特異的抗体－薬物コンジュゲート（ａｄｃ）
US20180244787A1 (en) 2016-12-22 2018-08-30 Sanofi Anti-human cxcr3 antibodies for treatment of vitiligo
CN110914298A (zh) 2016-12-22 2020-03-24 赛诺菲 具有耗减活性的人源化cxcr3抗体及其使用方法
EP3354278A1 (fr) 2017-01-31 2018-08-01 Sanofi Effet de protection des cellules neuronales d'anticorps spécifiques de la forme protofibrillaire du peptide bêta-amyloïde
JP2020514386A (ja) * 2017-03-22 2020-05-21 サノフイＳａｎｏｆｉ ヒト化抗ｃｘｃｒ５抗体を使用するループスの処置
TWI808963B (zh) * 2017-03-22 2023-07-21 法商賽諾菲公司 使用人類化抗ｃｘｃｒ５抗體治療狼瘡
US10781265B2 (en) * 2017-05-24 2020-09-22 Development Center For Biotechnology Humanized antibodies against Globo H and uses thereof in cancer treatments
RU2019142330A (ru) 2017-06-30 2021-07-30 Займворкс, Инк. Стабилизированные химерные fab
US10875915B2 (en) * 2017-12-01 2020-12-29 Pfizer Inc. Anti-CXCR5 antibodies and compositions and uses thereof
JP2021512103A (ja) 2018-01-31 2021-05-13 バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｎａｍｐｔ阻害剤を含む抗体薬物複合体（ａｄｃｓ）
WO2019159193A1 (fr) * 2018-02-13 2019-08-22 Indian Institute Of Technology Bombay Nouveau récepteur antigénique chimérique anti-cd19 humanisé, séquence d'acide nucléique associée et préparation correspondante
AU2019242586A1 (en) * 2018-03-26 2020-10-01 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
WO2019243159A1 (fr) * 2018-06-18 2019-12-26 Bayer Aktiengesellschaft Conjugués liant-principe actif inhibant cxcr5 comprenant des éléments de liaison pouvant être fragmentés de manière enzymatique et présentant un profil d'action amélioré
EP3753954A1 (fr) 2019-06-21 2020-12-23 Université de Franche-Comté Anticorps anti-cd123, récepteurs d'antigène chimériques anti-cd123 et lymphocytes t de récepteurs d'antigène chimériques anti-cd123
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
EP4090365A1 (fr) 2020-01-15 2022-11-23 Immatics Biotechnologies GmbH Protéines de liaison à l'antigène se liant de manière spécifique à prame
BR112022016999A2 (pt) 2020-02-28 2022-10-25 Genzyme Corp Polipeptídeos de ligação modificados para conjugação de fármacos otimizada
WO2023010483A1 (fr) * 2021-08-05 2023-02-09 Hifibio (Hk) Limited Anticorps anti-cxcr5 humain et ses utilisations
WO2021214221A1 (fr) 2020-04-24 2021-10-28 Sanofi Combinaisons antitumorales contenant des conjugués d'anticorps anti-ceacam5 et du folfiri
CN115427082A (zh) 2020-04-24 2022-12-02 赛诺菲 含有抗ceacam5抗体缀合物和folfox的抗肿瘤组合
WO2021214222A1 (fr) 2020-04-24 2021-10-28 Sanofi Combinaisons antitumorales contenant des conjugués anticorps anti-ceacam5, de la trifluridine et du tipiracil
KR20230005176A (ko) 2020-04-24 2023-01-09 사노피 항-ceacam5 항체 콘쥬게이트 및 세툭시맙을 함유하는 항종양 조합물
AU2021335257A1 (en) 2020-09-04 2023-03-09 Merck Patent Gmbh Anti-CEACAM5 antibodies and conjugates and uses thereof
CN112521499B (zh) * 2020-12-24 2022-10-25 四川大学 抗cxcl13抗体及其用途
MX2023009100A (es) 2021-02-03 2023-09-25 Mozart Therapeutics Inc Agentes aglutinantes y métodos para usar los mismos.
TW202304984A (zh) * 2021-03-09 2023-02-01 香港商高誠生物醫藥（香港）有限公司 抗人類ｃｘｃｒ５抗體及其用途
WO2022241034A1 (fr) * 2021-05-12 2022-11-17 BioLegend, Inc. Anticorps anti-ccr8, fragments de liaison à l'antigène de ceux-ci, et agents et compositions et leurs procédés de fabrication et d'utilisation
CN113278072B (zh) * 2021-05-25 2023-06-20 河南凯普瑞生物技术有限公司 一种抗体的制备方法
CA3230246A1 (fr) * 2021-09-30 2023-04-06 Wenxin Xu Anticorps bispecifique et son application
WO2023076876A1 (fr) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation de réponses immunitaires à des vecteurs viraux
AU2022382383A1 (en) 2021-11-05 2024-06-20 Eli Lilly And Company Antitumor combinations containing anti-ceacam5 antibody-drug conjugates and anti-vegfr-2 antibodies
WO2023170240A1 (fr) 2022-03-09 2023-09-14 Merck Patent Gmbh Anticorps anti-ceacam5 et conjugués et leurs utilisations
WO2023172968A1 (fr) 2022-03-09 2023-09-14 Merck Patent Gmbh Anticorps anti-gd2, immunoconjugués et leurs utilisations thérapeutiques
WO2023212587A1 (fr) 2022-04-28 2023-11-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Polypeptides recombinants comprenant des anticorps à domaine unique ciblant herv-k sous-type hml-2
WO2024011077A2 (fr) 2022-07-04 2024-01-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Anticorps monoclonaux dirigés contre psd95 phosphorylée et leurs utilisations
CN117004700A (zh) * 2023-10-07 2023-11-07 北京爱博生生物技术有限公司 单克隆抗体可变区基因高通量测序的方法及其所用组合物与试剂盒

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (fr) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotique C-15003 PHO et sa préparation
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
WO1982001188A1 (fr) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd Composes 4,5-deoxymaytansinoide et leur procede de preparation
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
JP2532858B2 (ja) 1985-04-01 1996-09-11 セルテツク リミテツド 形質転換したミエロ―マ細胞系
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
EP0362371A4 (en) 1988-04-15 1990-10-24 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
WO1989009825A1 (fr) 1988-04-16 1989-10-19 Celltech Limited Procede de production de proteines d'adn recombinant
DE68921982D1 (de) 1988-06-14 1995-05-04 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
IL94611A (en) 1989-06-05 1994-12-29 Organogenesis Inc Medium for cell cultures containing insulin or growth factor similar to insulin, transferrin or iron ion, triiodothyronine or thyroxine and method of use
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU633698B2 (en) 1990-01-12 1993-02-04 Amgen Fremont Inc. Generation of xenogeneic antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
JP3319594B2 (ja) 1990-03-20 2002-09-03 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 定常領域の代わりに受容体結合性リガンドを有するキメラ抗体
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992003918A1 (fr) 1990-08-29 1992-03-19 Genpharm International, Inc. Animaux non humains transgeniques capables de produire des anticorps heterologues
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
JPH07500961A (ja) 1990-10-01 1995-02-02 ユニバーシティ オブ コネチカット 細胞による選択的内在化を目的としたウイルス及び細胞の標的設定
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
ATE218889T1 (de) 1990-11-09 2002-06-15 Stephen D Gillies Cytokine immunokonjugate
AU668870B2 (en) 1991-05-14 1996-05-23 Targetech, Inc Targeted delivery of genes encoding immunogenic proteins
EP0519596B1 (fr) 1991-05-17 2005-02-23 Merck & Co. Inc. Procédé pour réduire l'immunogénicité des domaines variables d'anticorps
AU2160992A (en) 1991-06-05 1993-01-12 Board Of Regents Acting For And On Behalf Of The University Of Michigan, The Targeted delivery of genes encoding secretory proteins
EP1400536A1 (fr) 1991-06-14 2004-03-24 Genentech Inc. Procédé pour fabriquer des anticorps humanisés
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
ATE275198T1 (de) 1991-12-02 2004-09-15 Medical Res Council Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken.
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
AU3434393A (en) 1992-01-17 1993-08-03 Regents Of The University Of Michigan, The Targeted virus
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
CA2076465C (fr) 1992-03-25 2002-11-26 Ravi V. J. Chari Conjugues agents de liaison cellulaire d'analogues et de derives de cc-1065
CA2133411A1 (fr) 1992-04-03 1993-10-14 Alexander T. YOUNG Therapie genique a l'aide de vecteurs viraux specifiques
WO1993021319A1 (fr) 1992-04-08 1993-10-28 Cetus Oncology Corporation ANTICORPS HUMANISES SPECIFIES PAR C-erbB-2
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
JPH08501085A (ja) 1992-08-26 1996-02-06 プレジデント アンド フェローズ オブ ハーバード カレッジ 抗腫瘍剤としてのサイトカインｉｐ−１０の利用
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
JP3789930B2 (ja) 1992-10-09 2006-06-28 アドバンスド ティシュー サイエンシズ，インコーポレーテッド 肝予備細胞
AU680459B2 (en) 1992-12-03 1997-07-31 Genzyme Corporation Gene therapy for cystic fibrosis
AU6796094A (en) 1993-04-29 1994-11-21 Raymond Hamers Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of (camelidae)
US6165463A (en) 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
EP1978033A3 (fr) 1995-04-27 2008-12-24 Amgen Fremont Inc. Anticorps humains dérivés à partir de xénosouris immunisée
CA2219486A1 (fr) 1995-04-28 1996-10-31 Abgenix, Inc. Anticorps humains derives de xeno-souris immunisees
JPH11514853A (ja) 1995-09-08 1999-12-21 ジエンザイム コーポレイション 遺伝子治療のための改良されたａａｖベクター
AU5711196A (en) 1996-03-14 1997-10-01 Human Genome Sciences, Inc. Apoptosis inducing molecule i
WO1997034631A1 (fr) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Domaines analogues a l'immunoglobuline a demi-vies prolongees
CA2248868A1 (fr) 1996-03-22 1997-09-25 Human Genome Sciences, Inc. Molecule ii inductrice d'apoptose
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
WO1998023289A1 (fr) 1996-11-27 1998-06-04 The General Hospital Corporation Modulation de la fixation de l'igg au fcrn
CA2616914C (fr) 1996-12-03 2012-05-29 Abgenix, Inc. Anticorps de liaison de recepteur d'egf
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
CZ294425B6 (cs) 1997-04-14 2005-01-12 Micromet Ag Způsob výroby anti-humánního antigenového receptoru, anti-humánní antigenový receptor, řetězec VH a VL, souprava pro selekci anti-humánních antigenových receptorů a farmaceutická kompozice, obsahující uvedený receptor
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6642051B1 (en) 1997-10-21 2003-11-04 Targeted Genetics Corporation Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors
EP1042343B1 (fr) 1997-11-03 2008-01-23 Human Genome Sciences, Inc. Vegi, un inhibiteur de l'angiogenese et de la croissance tumorale
AU770952B2 (en) 1999-03-01 2004-03-11 Genentech Inc. Antibodies for cancer therapy and diagnosis
EP2267026A1 (fr) 2000-04-12 2010-12-29 Human Genome Sciences, Inc. Protéine de fusion d'albumine
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
EP1317284A2 (fr) * 2000-09-08 2003-06-11 Micromet AG Constructions d'anticorps et/ou de chimiokine qui se lie a un recepteur chimiokine et leur utilisation contre des troubles immunologiques
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
MXPA04006136A (es) * 2001-12-21 2004-11-01 Anormed Inc Compuestos heterociclicos que se unen a receptor de quimiocina con eficacia incrementada.
US7470775B2 (en) * 2002-06-07 2008-12-30 The United States Of America As Represented By The Department Of Health And Human Services Anti-CD30 stalk and anti-CD30 antibodies suitable for use in immunotoxins
WO2004015426A1 (fr) * 2002-08-06 2004-02-19 Bayer Healthcare Ag Agents diagnostiques et therapeutiques contre des maladies associees au recepteur 5 de la chemokine cxc humain (cxcr5)
TW200530269A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
KR101200133B1 (ko) * 2004-06-01 2012-11-13 제넨테크, 인크. 항체 약물 접합체 및 방법
US20060148009A1 (en) 2004-10-12 2006-07-06 Xencor, Inc. Prediction and assessment of immunogenicity
GB0607774D0 (en) * 2006-04-20 2006-05-31 Renovo Group Plc Medicaments
TW200813086A (en) * 2006-05-11 2008-03-16 Hoffmann La Roche Immunereconstituted mouse
NO2195023T3 (fr) 2007-08-29 2018-08-04

Also Published As

Publication number Publication date
ES2672769T3 (es) 2018-06-18
DK2195023T3 (en) 2018-06-18
NZ583605A (en) 2012-10-26
ECSP109985A (es) 2010-03-31
KR20150082692A (ko) 2015-07-15
SI2195023T1 (en) 2018-07-31
SG10201407388XA (en) 2015-01-29
TN2010000092A1 (en) 2011-09-26
UY31309A1 (es) 2009-03-31
PL2195023T3 (pl) 2018-08-31
CN104017079A (zh) 2014-09-03
NO2195023T3 (fr) 2018-08-04
EP2195023A4 (fr) 2012-09-05
CA2698203C (fr) 2018-09-11
CO6270238A2 (es) 2011-04-20
WO2009032661A1 (fr) 2009-03-12
EP2195023A1 (fr) 2010-06-16
MX338397B (es) 2016-04-15
MX2010001975A (es) 2010-03-10
TW200918558A (en) 2009-05-01
JP2017123866A (ja) 2017-07-20
US20220073629A1 (en) 2022-03-10
HRP20180873T1 (hr) 2018-07-13
RU2015147300A (ru) 2019-01-11
US20180100019A1 (en) 2018-04-12
CN101842115A (zh) 2010-09-22
DOP2010000069A (es) 2010-03-31
IL238505A (en) 2017-05-29
CN101842115B (zh) 2014-07-30
AU2008296538B2 (en) 2014-08-14
RS57273B1 (sr) 2018-08-31
PE20090993A1 (es) 2009-07-08
PA8794201A1 (es) 2009-07-23
TWI439468B (zh) 2014-06-01
CR11293A (es) 2010-03-23
CR20150054A (es) 2015-04-06
US9243067B2 (en) 2016-01-26
NI201000281A (es) 2012-02-21
US20170044263A1 (en) 2017-02-16
RU2571515C2 (ru) 2015-12-20
MX338474B (es) 2016-04-18
MX346172B (es) 2017-03-10
CA2698203A1 (fr) 2009-03-12
US8647622B2 (en) 2014-02-11
EP2195023B1 (fr) 2018-03-07
CY1120665T1 (el) 2019-12-11
AR068354A1 (es) 2009-11-11
BRPI0815983A2 (pt) 2018-05-22
US20130243783A1 (en) 2013-09-19
KR20140117638A (ko) 2014-10-07
AU2008296538A1 (en) 2009-03-12
AU2008296538A2 (en) 2010-06-03
KR20100061815A (ko) 2010-06-09
KR101599704B1 (ko) 2016-03-07
CN111909273B (zh) 2024-03-26
US20130243793A1 (en) 2013-09-19
TWI608017B (zh) 2017-12-11
AR112564A2 (es) 2019-11-13
UA117446C2 (uk) 2018-08-10
JP6129152B2 (ja) 2017-05-17
EP3354662A1 (fr) 2018-08-01
RU2010111751A (ru) 2011-10-10
CL2008002565A1 (es) 2009-01-16
TW201425337A (zh) 2014-07-01
EP3792284A1 (fr) 2021-03-17
IL204173A (en) 2015-06-30
CN104017078B (zh) 2020-09-08
JP5743543B2 (ja) 2015-07-01
KR20140121486A (ko) 2014-10-15
MY159201A (en) 2016-12-30
US20130251714A1 (en) 2013-09-26
CN104017078A (zh) 2014-09-03
NI201000028A (es) 2012-02-21
HUE037489T2 (hu) 2018-08-28
LT2195023T (lt) 2018-06-25
JP2010537636A (ja) 2010-12-09
US8980262B2 (en) 2015-03-17
JP2015096075A (ja) 2015-05-21
US20110027266A1 (en) 2011-02-03
US9175087B2 (en) 2015-11-03
US9228019B2 (en) 2016-01-05
TW201630939A (zh) 2016-09-01
US20130246035A1 (en) 2013-09-19
TR201807983T4 (tr) 2018-06-21
MX338395B (es) 2016-04-15
EP3354662B1 (fr) 2020-08-19
UA104715C2 (en) 2014-03-11
CN104017079B (zh) 2017-01-04
KR101701140B1 (ko) 2017-02-01
US20130236476A1 (en) 2013-09-12
IL238505A0 (en) 2015-06-30
ZA201001514B (en) 2011-04-28
TWI574976B (zh) 2017-03-21
KR101667944B1 (ko) 2016-10-20
PH12015500248A1 (en) 2018-06-25
US9815902B2 (en) 2017-11-14
TW201741341A (zh) 2017-12-01
CN111909273A (zh) 2020-11-10
PT2195023T (pt) 2018-06-08
SV2010003494A (es) 2011-01-25

Similar Documents

Publication Publication Date Title
MA31821B1 (fr) Anticorps anti-cxcr5 humanises, leurs derives et leurs utilisations
MA44312A (fr) Anticorps et leurs méthodes d&#39;utilisation
MA31838B1 (fr) Anticorps se liant à l&#39;il-4 et/ou à l&#39;il-3 et leurs utilisations
TNSN07398A1 (fr) Anticorps contre la p-cadherine
MA46708B1 (fr) Anticorps anti-pd1 et leurs utilisations
MA42622B1 (fr) Agents de liaison à tigit et leurs utilisations
TW200603828A (en) Treatment of disorders
GEP20074252B (en) Antibodies to vla-1
MA31767B1 (fr) Composes organiques et leurs utilisations
MA30673B1 (fr) Composes et procedes d&#39;inhibition de l&#39;interaction de proteines bcl avec des partenaires de liaison
MA40041A (fr) Anticorps anti-gitr et leurs procédés d&#39;utilisation
TW200642694A (en) Anti-M-CSF antibody compositions
WO2006122257A3 (fr) Nebulisation d&#39;anticorps monoclonaux pour le traitement de maladies pulmonaires
MA30557B1 (fr) Composés de pyrrolopyrimidine et leurs utilisations.
MA32099B1 (fr) Composition comprenant un anticorps se liant au domaine ii de her2 et variantes acides de celle-ci
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
NZ599628A (en) Axl antibodies
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
WO2008051797A3 (fr) Anticorps d&#39;agonistes anti-notch3 et leur utilisation dans le traitement de maladies liées à notch3
MA30156B1 (fr) Immunoglobulines
MA37761A1 (fr) Protéines de liaison à un antigène antagoniste d&#39;un double récepteur et leurs utilisations
MY149492A (en) Immunoglobulins directed against nogo
MA29723B1 (fr) Composes
MA33753B1 (fr) Nouveaux camphènes arylés, procédés de préparation et utilisations de ceux-ci
UA94211C2 (ru) Выделенное полностью человеческое моноклональное cd3 антитело